open
serve
block
verse
w
o
rdys
billionaire
.ai
your
list
Whiteboard
App
quizie
un
school
New Journal
News
Home
Politics
World
Sports
Markets
Business
Entertainment
Music
Health
Tech
Science
Good News
Ask Genius
Apps
IJR News — today's news from every side
Ask Genius
Apps
Trending
📊 Approval movers
Donald Trump
100%
Novo says Wegovy trial moved 40% of young children out of obesity
x/wegovy
— 4h
In Novo Nordisk's STEP Young phase 3 trial, once-weekly semaglutide plus lifestyle changes reduced BMI and 40.4% of children aged 6-11 with obesity no longer met obesity criteria after 68 weeks, versus 0% on placebo. Safety remained consistent with prior semaglutide studies, adding to the growing body of pediatric obesity treatment data.
+3
3
Share
Chris Dalton
Glad there's finally something beyond diet and exercise lectures for kids who genuinely struggle, this could change a lot of families' lives.
GLP-1 obesity drugs linked to fewer alcohol hospitalizations
Health
— Jul 21, 2026
A multi-trial analysis of about 40,700 adults found GLP-1 receptor agonists such as semaglutide and tirzepatide are associated with substantially lower alcohol-related hospital admissions across diabetics, obesity, and alcohol-use disorder groups, with reductions ranging from roughly 26% to 65% depending on the comparison. Experts say the findings hint at a potential role for these weight‑loss and diabetes drugs in treating alcohol-use disorders, though more research is needed to confirm causality and guide use.
+6
Share
